Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma

著者: Sophia Gayle, Sean F. Landrette, Neil Beeharry, Chris Conrad, Marylens Hernandez, Paul Beckett, Shawn M. Ferguson, Talya Mandelkern, Meiling Zheng, Tian Xu, Jonathan M. Rothberg, Henri S. Lichenstein - Blood 2017 被引用: 206

were identified as important determinants of apilimod sensitivity. These findings thus suggest that disruption of lysosomal homeostasis with apilimod represents a novel approach to treat B-NHL.